Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Antibody Discovery Services and Platforms Market (3rd Edition) by Service Offered, by Antibody Discovery Method, by Nature of Antibody Generated and by Key Geographies: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
"Antibody Discovery: Services and Platforms Market (3rd Edition), 2020-2030" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry over the next ten years.
The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics.
One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade. Based on parameters, such as the overall R&D expenditure available to CROs, percentage of R&D expenses incurred in each discovery step, and outsourcing profile, we have provided an informed estimate of the likely evolution of the antibody discovery services market in the mid to long term, for the time period 2020-2030.
With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry. In fact, they are presently estimated to constitute the largest class of biologics in the industry.
Examples of recently approved monoclonal antibody products include (in reverse chronological order) Adakveo (November 2019), Beovu (October 2019), SKYRIZIT (April 2019) and EVENITYT (April 2019). These molecules have high target specificities and favorable safety profiles.
Further, given the success of monoclonal antibodies, research on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, has also gained traction.
Companies Mentioned
- 3E Bioventures Capital
- 3SBio
- A*STAR's Genome Institute of Singapore
- Ab Initio Biotherapeutics
- Ab Studio
- ABBA Therapeutics
- AbBioSci
- AbbVie
- Abcam
- AbCellera
- Abcentra
- AbCheck
- Abeome
- AbGenics Life Sciences
- ABL Bio
- Ablexis
- Abpro
- Absolute Antibody
- AbVision
- Abwiz Bio
- Abzena
- Abzyme Therapeutics
- AC Immune
- Accel
- Acceleron Pharma
- Accurus Biosciences
- Achaogen
- ACYTE Biotech
- Adagene
- Adaptate Biotherapeutics
- Adimab
- Aduro Biotech
- Advantech
- Advantech Capital
- AffinityImmuno
- Affitech
- Agency for Science, Technology and Research
- Agenus
- AIMM Therapeutics
- Aimmune Therapeutics
- Aisling Capital
- Akeagen
- Akeso Biopharma
- Aldevron
- Alector
- Alligator Bioscience
- Allogene Therapeutics
- Alloy Therapeutics
- Ally Bridge Group
- Alta Partners
- Alzheimer's Drug Discovery Foundation
- Amgen
- Amgen Ventures
- Ampersand Capital Partners
- AnaImmune
- Analytics Engine
- AnaptysBio
- Andera Partners
- Antagene
- Antibody Design Labs
- Antibody Solutions
- Antiverse
- AP Biosciences
- Apexigen
- Aptevo Therapeutics
- Aquila BioMedical
- Aquila Capital
- Aquilo Capital Management
- Aragen Bioscience
- ARCH Venture Partners
- Arcus Biosciences
- argenx
- Aridis Pharmaceuticals
- Aro Biotherapeutics
- Aronora
- Arsanis
- Artizan Biosciences
- Assistant Secretary for Preparedness and Response
- Astellas Pharma
- AstraZeneca
- aTen Therapeutics
- Atreca
- Autolus Therapeutics
- AvantGen
- AVIC Capital
- AxioMx
- Ballast Point Ventures
- Bayer
- BBI Group
- BeiGene
- Beijing Shijilongxin Investment
- Berkeley Lights
- Betta Pharmaceuticals
- Bhami's Research Laboratory
- Bharat Innovation Fund
- Bill & Melinda Gates Foundation
- BioAtla
- Biocytogen
- BioDiscovery
- BioDuro
- Biogen
- BioInvent
- Biomatics Capital
- BioNTech
- Bio-Rad Laboratories
- BioSavita
- Biosion
- Biotechnology Value Fund
- Biotecnol
- BIOTEM
- Biotheus
- Birchmere Labs
- Bird Rock Bio
- Blue Sky BioServices
- bluebird bio
- Boehringer Ingelheim
- Boston Children's Hospital
- Boxer Capital
- Brain Canada
- Bristol-Myers Squibb
- Broteio Pharma
- Burrage Capital
- CALIXAR
- CANbridge
- Cancer Prevention and Research Institute of Texas
- Carterra
- Catalent Biologics
- CBC Group
- CCB Capital
- CDH Investments
- CDI Laboratories
- Celexion
- Celgene
- Cell Signaling Technology
- Celsius Therapeutics
- Centers for Disease Control and Prevention (CDC)
- Charles River Laboratories
- ChemBio Discovery Solutions
- Chemical Abstracts Service (CAS)
- ChemPartner
- Chia Tai Tianqing Pharmaceutical
- China Life Investment Holding
- China Life Private Equity Investment
- ChinaEquity Group (CEG)
- Chiome Bioscience
- Chugai Pharmabody Research
- Chugai Pharmaceutical
- Cilag
- Citryll
- City of Hope
- Columbia University Irving Medical Center
- Compass Therapeutics
- Cormorant Asset Management
- Corvidia Therapeutics
- Cosmo Bio
- Cowen Healthcare Investments
- Cowin Venture Capital
- CR-CP Life Science Fund
- Creative Biolabs
- Creative Biostructure
- Creative Diagnostics
- Crescendo Biologics
- Crystal Bioscience
- CSL Behring
- CStone Pharmaceuticals
- CureVac
- CUSABIO TECHNOLOGY
- DAFNA Capital Management
- Daiichi Sankyo
- Dako
- Dana-Farber Cancer Institute
- DCVC (Data Collective)
- DaTaMabs
- Decheng Capital
- Defense Advanced Research Projects Agency (DARPA)
- Delian Capital
- Denali Therapeutics
- Dianomi Therapeutics
- Diatheva
- Digital Proteomics
- Distributed Bio
- DJS Antibodies
- Early Drug Development Group (E2DG)
- EcoR1 Capital
- Efung Capital
- Eight Roads
- Eisai
- Eli Lilly and Company
- Elpis Biopharmaceuticals
- Emergent BioSolutions
- Enterprise Singapore
- Enthera
- Entos Pharmaceuticals
- EpimAb Biotherapeutics
- Epiphron Capital Group
- Eureka Therapeutics
- European Investment Bank
- European Molecular Biology Laboratory (EMBL)
- Eurostars
- Evotec
- Exelixis
- Exiris
- exonbio
- FairJourney Biologics
- Faron Pharmaceuticals
- FCMI Parent
- Ferring Pharmaceuticals
- Five Prime Therapeutics
- Flagship Pioneering
- Flanders Innovation and Entrepreneurship
- Floodgate
- ForteBio
- Fortune Capital Services
- Forty Seven
- F-Prime Capital
- Fred Hutchinson Cancer Research Center
- FREJOY Investment Management
- Fusion Antibodies
- Fusion Pharmaceuticals
- G&P Biosciences
- G.N. Tech Venture
- Genagon Therapeutics
- Genedata Biologics
- GeneFrontier
- Geneious Biologics
- General Atlantic
- Genmab
- Genor Biopharma
- GenScript
- GHO Capital
- GIC
- GigaGen
- Gilead Sciences
- Glenmark Pharmaceuticals
- Glythera
- Gopher Asset Management
- GP Healthcare Capital
- Grenoble Alpes University Hospital
- Grifols
- GlaxoSmithKline
- Gustave Roussy
- GV20 Oncotherapy
- H3 Biomedicine
- Harbour BioMed
- Harpoon Therapeutics
- HD Biosciences
- Henlix Biotech
- Heptares Therapeutics
- Hercules Capital
- Heritas Capital Management
- HiFiBiO Therapeutics
- Hillhouse Capital Group
- HJB
- Hony Capital
- HOPU Investments
- Huaxing Growth Capital
- Hummingbird Bioscience
- i2 Pharmaceuticals
- Ibex Biosciences
- Icosagen
- IDG Capital
- IFB Hamburg
- IGEM Therapeutics
- I-Mab Biopharma
- iMetabolic Biopharma
- Immatics Biotechnologies
- Immune Biosolutions
- Immune Pharmaceuticals
- ImmunoChina Pharmaceuticals
- ImmunoGenes
- Immunome
- Immunomic Therapeutics
- ImmunoPrecise Antibodies
- ImmunoQure
- In-Cell-Art
- Incyte
- Indivumed
- Inhibrx
- Innate Pharma
- Innogene Kalbiotech
- Innovate UK
- Innovative Targeting Solutions
- Innovent Biologics
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Institute for Research in Biomedicine
- Intarcia Therapeutics
- IntelliCyt
- Integral Molecular
- Invenra
- Invest Northern Ireland
- IONTAS
- IP Group
- Isogenica
- Italian National Institute of Health
- ITBMed
- iTeos Therapeutics
- Janssen Biotech
- JDRF T1D Fund
- Jiangsu Hengrui Medicine
- Johnson & Johnson Innovation
- Jounce Therapeutics
- Juno Therapeutics
- Just Biotherapeutics (Acquired by Evotec)
- Kadmon
- Kaken Pharmaceutical
- Keystone Capital Partners
- Kite Pharma
- Kodiak Sciences
- Kymab
- LakePharma
- LAMPIRE Biological Laboratories
- Lava Therapeutics
- Leading Biology
- Legend Capital
- Legend Star
- Leidos Biomedical Research
- LEO Pharma
- LG Chem
- Life Science Partners
- LifeArc
- Ligand Pharmaceuticals
- Light Chain Bioscience
- Lilly Ventures
- Lineage Biosciences (Acquired by AbCellera)
- Linear Venture
- Lipum
- Lonza
- Lundbeck
- LYFE Capital
- MAB Discovery
- Mablytics
- Mabpharm
- MabSpace Biosciences
- MabVax Therapeutics
- MacroGenics
- Magenta Therapeutics
- Maine Biotechnology Services
- Malin
- Massachusetts General Hospital
- MassBiologics
- Maverick Therapeutics
- MD Anderson Cancer Center
- MedAbome
- MedImmune
- MEMO Therapeutics
- Memorial Sloan Kettering Cancer Center
- Merck
- Merus
- MI-mAbs
- Mirae Asset Financial Group
- Mitsubishi Tanabe Pharma
- Mitsubishi UFJ Capital
- ModiQuest Research
- Molcure
- Molecular Devices
- Molecular Templates
- MolMed
- Moradec
- MorphoSys
- Mount Sinai Health System
- MPM Capital
- MRL Ventures Fund
- MSM Protein Technologies
- Mycenax Biotech
- National Cancer Institute
- National Centre for Biomolecular Research
- National Center for Research and Development
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of General Medical Sciences
- NanoString Technologies
- NB Health Laboratory
- NBE-Therapeutics
- NeoBiotechnologies
- NeoClone
- Neon Therapeutics
- neoX Biotech
- Nest.Bio Ventures
- Neurimmune
- New World TMT
- Nidus BioSciences
- NJCTTQ
- Nkarta Therapeutics
- North Coast Biologics
- NovaRock Biotherapeutics
- Novartis
- Novo Nordisk
- Numab Therapeutics
- NYU Langone Health
- Oceanpine Capital
- Olympic Protein Technologies
- Oncothyreon
- Ono Pharmaceutical
- Open Monoclonal Technology
- OrbiMed Advisors
- OREGA Biotech
- ORI Healthcare Fund
- OriGene Technologies
- OriMAbs
- Ossianix
- Oxford Sciences Innovation
- Paladin Capital Group
- Pandion Therapeutics
- Panoply Bio
- Pediatric Brain Tumor Consortium
- Penn Medicine
- Pennsylvania Industrial Development Authority
- Pfizer
- pH Pharma
- Phanes Therapeutics
- PharmAbcine
- PharmaLegacy
- Pierre Fabre
- Polaris Partners
- Potenza Therapeutics
- PPF Group
- Precision Antibody
- Protein Alternatives (PROALT)
- ProteoGenix
- ProtTech
- Proxima Ventures
- Purdue Pharma
- Pure Biologics
- PX'Therapeutics
- Qianhai Qinzhi Capital
- Qiming Venture Partners
- QIMR Berghofer Medical Research Institute
- QoolAbs
- Quan Funds
- Quebec Consortium for Drug Discovery (CQDM)
- Queen's University
- Redalpine Venture Partners
- Redmile Group
- Regeneron Pharmaceuticals
- Regione Lazio
- Resonant Therapeutics
- Retrogenix
- Revolve Biotechnologies
- Rezolute
- Rhenman & Partners Asset Management
- Roche
- RubrYc Therapeutics
- Rx Biosciences
- SAB Biotherapeutics
- Samsara BioCapital
- Samsara Networks
- San Diego Biomedical Research Institute
- Sanofi
- Sanyou Biopharmaceuticals
- SARomics Biostructures
- Schroder Adveq
- Sea Lane Biotechnologies
- SEEDS Capital
- Selecxine
- Sequoia Capital China
- Serum Institute of India
- Sevion Therapeutics
- Shanghai Junshi Biosciences
- Shenyang Sunshine Pharmaceuticals
- Shenzhen GTJA Investment Group
- Shenzhen Hepalink Pharmaceutical
- Shenzhen Innovation Capital Investment
- Shire
- Shilps Sciences
- Sichenzia Ross Ference
- Sichuan Kelun-Biotech Biopharmaceutical
- Siegfried Holding
- Silverton Partners
- Simcere Pharmaceutical
- Simon Fraser University
- Single Cell Technology
- Sino Biological
- Sinobioway
- SK Holdings
- Sofinnova Partners
- Sorrento Therapeutics
- SOTIO
- South Dakota Equity Partners
- Specifica
- Standford University
- State Development & Investment
- State of Wisconsin Investment Board (SWIB)
- Straterx
- Summit Partners
- Surface Oncology
- Surveyor Capital
- Sutro Biopharma
- Suzhou Oriza Holdings
- Syd Labs
- Symphogen
- Synbio Technologies
- Syngene
- TA Associates
- Takeda
- Talem Therapeutics
- Tanabe Research Laboratories
- Tasly Biopharmaceuticals
- Technical University of Denmark
- Telix Pharmaceuticals
- Temasek Holdings
- TeneoBio
- TESARO
- TetraGenetics
- Teva Pharmaceutical Industries
- TG Therapeutics
- The University of Texas MD Anderson Cancer Center
- The Wistar Institute
- Theraclone Sciences
- Theranyx
- Thermo Fisher Scientific
- Thiel Capital
- Third Point Ventures
- Third Venture Biopharma
- Tasgen Bio-Tech
- ThromboGenics
- Tizona Therapeutics
- Tmunity Therapeutics
- Torch Biosciences
- TRACON Pharmaceuticals
- Transcenta Holding
- Transgene
- TRIANNI
- Tri-Institutional Therapeutics Discovery Institute
- Tsinghua University
- Twist Bioscience
- UK Innovation & Science Seed Fund
- University College London
- University of Navarra
- University of Oxford
- University of Southampton
- University of Surrey
- University of Technology Sydney
- University of Texas
- U-Protein Express
- US Department of Defense
- Vaccinex
- Vall d'Hebron Institute of Oncology
- Valneva
- Velabs Therapeutics
- venBio
- Vertex Holdings
- VI Ventures
- Vinnova
- Vir Biotechnology
- Visterra
- Vital Venture Capital
- Viva Biotech
- Voyager Therapeutics
- Washington University School of Medicine
- Watson Investments
- Wellington Management
- Wisconsin Alumni Research Foundation
- Woodford Investment Management
- Woodford Patient Capital Trust
- WuXi AppTec
- Wuxi Biologics
- XBiotech
- xCella Biosciences
- Xencor
- XOMA
- Yale Cancer Center
- Yinuoke
- YUMAB
- Yurogen Biosystems
- Zai Lab
- Zebra Biologics
- Zhejiang Teruisi Pharmaceutical
- Zheshang Venture Capital
- Zumutor Biologics
- Zurich Cantonal Bank
- Zydus Cadila
- Zymeworks
For more information about this report visit https://www.researchandmarkets.com/r/omrdds
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.